The estimated Net Worth of Briseno Andres Ruiz is at least 1.27 百万$ dollars as of 9 February 2024. Mr Ruiz owns over 2,000 units of IDEAYA Biosciences stock worth over 888,022$ and over the last few years he sold IDYA stock worth over 380,140$.
Mr has made over 5 trades of the IDEAYA Biosciences stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 2,000 units of IDYA stock worth 92,040$ on 9 February 2024.
The largest trade he's ever made was selling 2,000 units of IDEAYA Biosciences stock on 9 February 2024 worth over 92,040$. On average, Mr trades about 1,667 units every 27 days since 2023. As of 9 February 2024 he still owns at least 24,531 units of IDEAYA Biosciences stock.
You can see the complete history of Mr Ruiz stock trades at the bottom of the page.
Andres Ruiz Briseno CPA is the VP and Head of Bus. Operations & IR at IDEAYA Biosciences.
Mr CPA is 34, he's been the VP and Head of Bus. Operations & IR of IDEAYA Biosciences since . There are 17 older and 1 younger executives at IDEAYA Biosciences. The oldest executive at IDEAYA Biosciences, Inc. is Wendy Yarno, 65, who is the Independent Director.
Briseno's mailing address filed with the SEC is C/O IDEAYA BIOSCIENCES, INC., 7000 SHORELINE COURT, SUITE 350, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 5 years, insiders at IDEAYA Biosciences have traded over 13,169,580$ worth of IDEAYA Biosciences stock and bought 2,220,527 units worth 22,722,236$ . The most active insiders traders include Partners L P/Ilbiotechnolog...、Timothy M Shannon、X L.P.Canaan Partners X Llc.... On average, IDEAYA Biosciences executives and independent directors trade stock every 29 days with the average trade being worth of 2,196,906$. The most recent stock trade was executed by Jason Throne on 27 June 2024, trading 53,484 units of IDYA stock currently worth 415,571$.
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
IDEAYA Biosciences executives and other stock owners filed with the SEC include: